Patents by Inventor Lori Jean VAN ORDEN
Lori Jean VAN ORDEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190119275Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 17, 2018Publication date: April 25, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20190106420Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 10, 2018Publication date: April 11, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
-
Patent number: 10208040Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: March 8, 2018Date of Patent: February 19, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
-
Patent number: 10196393Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: March 8, 2018Date of Patent: February 5, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
-
Patent number: 10100049Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 2, 2016Date of Patent: October 16, 2018Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
-
Publication number: 20180258088Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 8, 2018Publication date: September 13, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20180258087Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 8, 2018Publication date: September 13, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Patent number: 9669027Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 15, 2015Date of Patent: June 6, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Publication number: 20170121327Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 2, 2016Publication date: May 4, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
-
Patent number: 9260414Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 12, 2014Date of Patent: February 16, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Publication number: 20160038483Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: October 15, 2015Publication date: February 11, 2016Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Patent number: 9212168Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 2, 2012Date of Patent: December 15, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Patent number: 9206159Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: April 24, 2013Date of Patent: December 8, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lori Jean Van Orden, Gavin Ogawa, Donna Wilton
-
Publication number: 20150071878Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Patent number: 8921372Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 3, 2011Date of Patent: December 30, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa, Xiaojun Huang, Weijiang Zhang
-
Patent number: 8637568Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: GrantFiled: July 8, 2013Date of Patent: January 28, 2014Assignee: Theravance, Inc.Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
-
Publication number: 20130296322Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: July 8, 2013Publication date: November 7, 2013Applicant: THERAVANCE, INC.Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
-
Publication number: 20130287730Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: April 24, 2013Publication date: October 31, 2013Inventors: Daniel D. Long, Robert Murray McKinnell, Lori Jean Van Orden, Gavin Ogawa, Donna Wilton
-
Patent number: 8501964Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: GrantFiled: December 1, 2011Date of Patent: August 6, 2013Assignee: Theravance, Inc.Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
-
Publication number: 20130115194Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Inventors: Daniel D. LONG, Robert Murray MCKINNELL, Lan JIANG, Mandy LOO, Kassandra LEPACK, Lori Jean VAN ORDEN, Gavin OGAWA, Xiaojun HUANG, Weijiang ZHANG
